Abstract: It is provided a nanogel compound comprising a) a nanogel matrix component chosen from the group consisting of poly(N-isopropylacrylamide), poly(N-isopropyl methacrylamide), poly(N,N-diethylacrylamide), poly(N-ethylmethacrylamide), polyglycerol, polyglycerol derivatives and combinations thereof and b) a first or second conjugation component which forms an interpenetrating or semi-interpenetrating network with the nanogel matrix component. Thereby, the first conjugation component is a charged component chosen from the group consisting of acids, methacrylates, methacrylamides, acrylamides and combinations thereof and the second conjugation component is a conjugated polymer chosen from the group consisting of polyaniline, polypyrrole, poly(N—(C1-C10)alkyl aniline), poly(3,4-ethylenedioxythiophene), 2-ethylhexylcyclopentadithiophene-co-2,1,3-benzothiadiazole, 2-ethylhexylcyclopentadithiophene-co-2,1,3-benzoselenadiazole, and combinations thereof.

Abstract: The present invention relates to a drug polymer conjugate comprising a pharmaceutically active compound and a dendritic polyglycerol, as well as to a drug polymer conjugate comprising a pharmaceutically and/or diagnostically active compound bound to a dendritic polyglycerol core having a polyethylene glycol shell.